Archive for November, 2011
« Previous Entries‘I don’t want to die’: assisted suicide advocate – CTV.ca
Wednesday, November 30th, 2011
'I don't want to die': assisted suicide advocateCTV.caShe was diagnosed with amyotrophic lateral sclerosis two years ago, and since then has watched her health and independence slip away. "I am slowly dying, piece by piece, day by day," she told reporters. "I must make this very clear: I do not want to …and more »
Cytokinetics Says Lou Gehrig’s Disease Drug Safe – BusinessWeek
Wednesday, November 30th, 2011Cytokinetics Says Lou Gehrig's Disease Drug SafeBusinessWeekThree patients with the disease, amyotrophic lateral sclerosis, saw their symptoms decrease, said Robert Blum, Cytokinetics chief executive officer. “Even after two weeks, in this study we saw trends toward improvement,” Blum said in an interview. ALS …Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS …MarketWatch [...]
‘I don’t want to die’: assisted suicide proponent – CTV.ca
Wednesday, November 30th, 2011'I don't want to die': assisted suicide proponentCTV.caShe was diagnosed with amyotrophic lateral sclerosis two years ago, and since then has watched her health and independence slip away. "I am slowly dying, piece by piece, day by day," she told reporters. "I must make this very clear: I do not want to …and more »
Cytokinetics Says Mid-stage Trial Of CK-2017357 Positive In ALS Patients – NASDAQ
Wednesday, November 30th, 2011Cytokinetics Says Mid-stage Trial Of CK-2017357 Positive In ALS PatientsNASDAQ(RTTNews) – Cytokinetics, Inc.(CYTK) Wednesday said its CK-2017357 trial reported a positive result in Part A of a continuing mid-stage trial of defining the tolerability and pharmacokinetic profile in patients with amyotrophic lateral sclerosis or ALS …
Two moving AMEX Stocks around a Buck: AEN and XFN – Beacon Equity Research
Wednesday, November 30th, 2011Two moving AMEX Stocks around a Buck: AEN and XFNBeacon Equity ResearchGet my next ALERT 100% FREE AEN a developer of innovative disease-modifying medicines for serious illnesses, announced today that the Company's clinical collaborator for amyotrophic lateral sclerosis (ALS), PNA Center for Neurological Research (PNA), …Cytokinetics Announces Positive Results From Phase II Clinical Trial …MarketWatch [...]
Adeona Reports Positive Results For Initial Zinc Trial In Lou Gehrig’s Disease – NASDAQ
Wednesday, November 30th, 2011Adeona Reports Positive Results For Initial Zinc Trial In Lou Gehrig's DiseaseNASDAQ(RTTNews) – Adeona Pharmaceuticals, Inc. (AEN) Wednesday said PNA Center for Neurological Research's pilot Zinc Therapy was found to be safe and recorded a slow disease progression in amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's …Positive Clinical Study Results Reported by [...]
Cytokinetics offers upbeat data from mid-stage trial of ALS drug – FierceBiotech
Wednesday, November 30th, 2011Cytokinetics offers upbeat data from mid-stage trial of ALS drugFierceBiotechThe trial, involving 24 patients with amyotrophic lateral sclerosis (ALS), commonly called Lou Gehrig's disease, showed the drug was well-tolerated at daily doses ranging from 125 mg and 375 mg. It reported that 83% of patients on various doses of the …Cytokinetics Announces Positive Results From [...]
Cytokinetics Says Lou Gehrig’s Disease Drug Safe in Study – BusinessWeek
Wednesday, November 30th, 2011Cytokinetics Says Lou Gehrig's Disease Drug Safe in StudyBusinessWeekThree patients with the disease, amyotrophic lateral sclerosis, saw their symptoms decrease, said Robert Blum, Cytokinetics chief executive officer. “Even after two weeks, in this study we saw trends toward improvement,” Blum said in an interview. …Cytokinetics Announces Positive Results From Phase II Clinical Trial …MarketWatch (press [...]
Cytokinetics Says Experimental ALS Drug Safe in Early Study – BusinessWeek
Wednesday, November 30th, 2011Cytokinetics Says Experimental ALS Drug Safe in Early StudyBusinessWeekThe ALS therapy, CK-2017357, caused mild dizziness in some of the 24 patients in the second of three trials typically required for US regulatory approval, the San Francisco-based company said today in a statement. Three patients saw their symptoms …Cytokinetics Announces Positive Results From Phase II Clinical [...]
Research and Markets: Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2011 – Benzinga (press release)
Wednesday, November 30th, 2011Research and Markets: Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2011Benzinga (press release)A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and …and more »
« Previous Entries